Aligos Therapeutics (ALGS) officer awarded 23,310 stock options at $7.03 strike

Rhea-AI Filing Summary

Aligos Therapeutics reported that officer Julian A. Symons received a grant of stock options as part of his compensation. The award covers 23,310 stock options to buy Aligos common stock at an exercise price of $7.03 per share.

These options were granted on March 9, 2026 and vest over time. According to the terms, 1/48th of the options vest each month, starting from March 9, 2026, so that the entire grant becomes fully vested and exercisable on the fourth anniversary of that date, if he continues in service through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Symons Julian A.

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.03	03/09/2026		A		23,310		(1)	03/09/2036	Common Stock	23,310	$0	23,310	D

Explanation of Responses:

1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Executive Vice President, Chief Scientific Officer

	/s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aligos Therapeutics (ALGS) report for Julian A. Symons?

Aligos Therapeutics reported that officer Julian A. Symons received a stock option grant for 23,310 shares. These options give him the right to buy Aligos common stock at a set price as part of his equity-based compensation package.

How many Aligos Therapeutics (ALGS) options were granted to Julian A. Symons and at what price?

Julian A. Symons was granted 23,310 stock options for Aligos Therapeutics common stock at an exercise price of $7.03 per share. This exercise price is the fixed cost he would pay per share if he chooses to exercise the options.

How do the new Aligos Therapeutics (ALGS) stock options vest for Julian A. Symons?

The 23,310 stock options vest in 48 equal monthly installments starting March 9, 2026. Each month, 1/48th of the grant vests, so all options become fully vested and exercisable on the fourth anniversary, assuming continued service throughout the vesting period.

When will Julian A. Symons’ Aligos Therapeutics (ALGS) options be fully vested?

The options will be fully vested on the fourth anniversary of March 9, 2026. Monthly vesting of 1/48th of the 23,310 options occurs over 48 months, contingent on Julian A. Symons’ continued service with the company through each vesting date.

Are the Aligos Therapeutics (ALGS) options for Julian A. Symons an open-market purchase or a compensation grant?

The reported transaction is a compensation-related grant, not an open-market purchase. The Form 4 shows a code A transaction, described as a grant, award, or other acquisition of 23,310 stock options with a $7.03 per share exercise price.